PT  - JOURNAL ARTICLE
AU  - Kastrukoff, L. F.
AU  - Oger, J. J.
AU  - Hashimoto, S. A.
AU  - Sacks, S. L.
AU  - Li, D. K.
AU  - Palmer, M. R.
AU  - Koopmans, R. A.
AU  - Petkau, A. J.
AU  - Berkowitz, J.
AU  - Paty, D. W.
TI  - Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation
AID  - 10.1212/WNL.40.3_Part_1.479
DP  - 1990 Mar 01
TA  - Neurology
PG  - 479--479
VI  - 40
IP  - 3 Part 1
4099  - http://n.neurology.org/content/40/3_Part_1/479.short
4100  - http://n.neurology.org/content/40/3_Part_1/479.full
SO  - Neurology1990 Mar 01; 40
AB  - A randomized, double-blind, placebo-controlled, noncrossover trial determined the efficacy of lymphoblastoid interferon (IFN) in chronic progressive multiple sclerosis (CP MS). Fifty patients received 5 × lo6 IUIFN subcutaneously daily for 6 months while 50 received placebo. After 2 years, there were no significant differences between the 2 groups based on clinical evaluations and quantitative MRI analysis of the brain, although a trend was observed in the IFN group. Clinically, the IFN group was worse at 1 and 3 months and improved at 6 to 18 months, when compared with the placebo group. Results of MRI evaluations of the brain at 6 months support this trend. This trend likely resulted from a subpopulation of 10 IFN-treated patients, characterized by a higher women: men ratio and a lower EDSS score at entry into the trial. We cannot recommend lymphoblastoid IFN as treatment for CP MS at this time.